Related Experiment Video
Updated: Jan 31, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges
Maria Diab1, Asfar Azmi1, Ramzi Mohammad1
1a Department of Oncology, Karmanos Cancer institute , Wayne State University , Detroit , MI , USA.
Introduction:
Despite many efforts to improve the outcome of pancreatic ductal adenocarcinoma (PDAC), its prognosis remains poor, which is mostly related to late diagnosis and drug resistance. Improving systemic therapy is considered the major challenge in improving the outcome of this disease.
Areas Covered:
This review covers novel chemotherapy and targeted agents in the treatment of PDAC, with a focus on advanced stage disease.
Expert Opinion:
Current frontline therapies used in the treatment of patients with PDAC with favorable performance status are gemcitabine (GEM) and nab-paclitaxel or 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). PDAC has a number of genetic mutations that may explain its biological behavior, such as KRAS, p53 and CDK2NA, which occur in more than 90% of cases. Unfortunately, to this day, a specific targeting agent to any of those frequent gene mutations is lacking. Emerging areas of targeted therapies include the DNA repair, stroma, metabolism, and stem cells. Immunotherapy with either vaccines or immune checkpoint inhibitors has not produced any significant improvements in outcome of PDAC. Incorporating different approaches in therapy, including conventional, immunological, and others, is key in offering patients with the best possible care.
Insights
Pancreatic ductal adenocarcinoma (PDAC) treatment faces challenges due to late diagnosis and drug resistance. This review explores novel chemotherapy and targeted agents for advanced PDAC, aiming to improve patient outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, often due to late detection and resistance to therapies.
- Improving systemic treatment is critical for enhancing patient outcomes in PDAC.
Purpose of the Study:
- This review focuses on novel chemotherapy and targeted agents for advanced-stage PDAC.
- It aims to provide an overview of emerging therapeutic strategies.
Main Methods:
- Literature review of current and emerging treatments for PDAC.
- Analysis of novel chemotherapy, targeted agents, and immunotherapies.
Main Results:
- Current frontline therapies include gemcitabine (GEM) plus nab-paclitaxel or FOLFIRINOX.
- Targeted therapies are emerging in areas like DNA repair, stroma, metabolism, and stem cells.
- Immunotherapy has not yet shown significant benefits for PDAC.
Conclusions:
- Despite advances, specific targeted agents for common PDAC mutations (KRAS, p53, CDK2NA) are lacking.
- A combination of conventional, immunological, and novel approaches is essential for optimal PDAC patient care.
Related Concept Videos
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Persuasion Strategies
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...
Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:

